450 related articles for article (PubMed ID: 11743649)
21. Transitional cell bladder tumor: predicting recurrence and progression by analysis of microsatellite loss of heterozygosity in urine sediment and tumor tissue.
Fornari D; Steven K; Hansen AB; Jepsen JV; Poulsen AL; Vibits H; Horn T
Cancer Genet Cytogenet; 2006 May; 167(1):15-9. PubMed ID: 16682280
[TBL] [Abstract][Full Text] [Related]
22. Role of chromosome 9 in human bladder cancer.
Miyao N; Tsai YC; Lerner SP; Olumi AF; Spruck CH; Gonzalez-Zulueta M; Nichols PW; Skinner DG; Jones PA
Cancer Res; 1993 Sep; 53(17):4066-70. PubMed ID: 8358736
[TBL] [Abstract][Full Text] [Related]
23. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
24. Loss of heterozygosity, microsatellite instability and TP53 gene status in ovarian carcinomas.
Plisiecka-Hałasa J; Dansonka-Mieszkowska A; Kraszewska E; Dańska-Bidzińska A; Kupryjańczyk J
Anticancer Res; 2008; 28(2A):989-96. PubMed ID: 18507046
[TBL] [Abstract][Full Text] [Related]
25. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
[TBL] [Abstract][Full Text] [Related]
27. p53 gene mutation in recurrent superficial bladder cancer.
Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
[TBL] [Abstract][Full Text] [Related]
28. Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer.
Trkova M; Babjuk M; Duskova J; Benesova-Minarikova L; Soukup V; Mares J; Minarik M; Sedlacek Z
Cancer Lett; 2006 Oct; 242(1):68-76. PubMed ID: 16343743
[TBL] [Abstract][Full Text] [Related]
29. [Detailed mapping and clinical significance of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis].
Xu XF; Tang PZ; Cheng SJ
Ai Zheng; 2003 May; 22(5):452-7. PubMed ID: 12753701
[TBL] [Abstract][Full Text] [Related]
30. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
Oncogene; 2006 Apr; 25(18):2685-96. PubMed ID: 16532037
[TBL] [Abstract][Full Text] [Related]
31. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
32. p53 Gene mutations in superficial bladder cancer.
Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
[TBL] [Abstract][Full Text] [Related]
33. Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment.
Szarvas T; Kovalszky I; Bedi K; Szendroi A; Majoros A; Riesz P; Füle T; László V; Kiss A; Romics I
Oncol Rep; 2007 Aug; 18(2):405-9. PubMed ID: 17611663
[TBL] [Abstract][Full Text] [Related]
34. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas.
Jones TD; Eble JN; Wang M; MacLennan GT; Delahunt B; Brunelli M; Martignoni G; Lopez-Beltran A; Bonsib SM; Ulbright TM; Zhang S; Nigro K; Cheng L
Clin Cancer Res; 2005 Oct; 11(20):7226-33. PubMed ID: 16243792
[TBL] [Abstract][Full Text] [Related]
35. Microsatellite analysis of urine sediment versus urine cytology for diagnosing transitional cell tumors of the urinary bladder.
Fornari D; Steven K; Hansen AB; Vibits H; Jepsen JV; Poulsen AL; Schwartz M; Horn T
APMIS; 2004 Feb; 112(2):148-52. PubMed ID: 15056232
[TBL] [Abstract][Full Text] [Related]
36. Kinetic profiles by topographic compartments in muscle-invasive transitional cell carcinomas of the bladder: role of TP53 and NF1 genes.
Blanes A; Rubio J; Martinez A; Wolfe HJ; Diaz-Cano SJ
Am J Clin Pathol; 2002 Jul; 118(1):93-100. PubMed ID: 12109862
[TBL] [Abstract][Full Text] [Related]
37. Frequent association of p53 gene mutation in invasive bladder cancer.
Fujimoto K; Yamada Y; Okajima E; Kakizoe T; Sasaki H; Sugimura T; Terada M
Cancer Res; 1992 Mar; 52(6):1393-8. PubMed ID: 1540947
[TBL] [Abstract][Full Text] [Related]
38. Molecular evidence supporting field effect in urothelial carcinogenesis.
Jones TD; Wang M; Eble JN; MacLennan GT; Lopez-Beltran A; Zhang S; Cocco A; Cheng L
Clin Cancer Res; 2005 Sep; 11(18):6512-9. PubMed ID: 16166427
[TBL] [Abstract][Full Text] [Related]
39. p53 mutations and prognosis in bladder tumors.
Uchida T; Wada C; Ishida H; Wang C; Egawa S; Yokoyama E; Kameya T; Koshiba K
J Urol; 1995 Apr; 153(4):1097-104. PubMed ID: 7869472
[TBL] [Abstract][Full Text] [Related]
40. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.
Choi C; Cho S; Horikawa I; Berchuck A; Wang N; Cedrone E; Jhung SW; Lee JB; Kerr J; Chenevix-Trench G; Kim S; Barrett JC; Koi M
Genes Chromosomes Cancer; 1997 Nov; 20(3):234-42. PubMed ID: 9365830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
